(Reuters) – French laboratory Valneva said on Wednesday it expected its turnover to increase in 2024, thanks to growth in sales of its travel vaccines and the first sales of its chikungunya vaccine .
Total turnover should therefore be between 170 and 190 million euros in 2024, the group said.
“Our goal in 2024 is to continue to leverage the recovery of the travel industry to continue the commercial growth of our existing products and to successfully launch our chikungunya vaccine, Ixchiq,” Peter Bühler said in a statement. , CFO of Valneva.
The group has raised its sales forecasts for 2024, now expected to be between 160 million and 180 million euros.
It also plans R&D expenses lower than those communicated previously and between 60 million and 75 million euros, due to better visibility of its expenses linked to the chikungunya and Zika programs.
Valneva reports total revenue of €153.7 million in 2023, including €144.6 million in product sales.
The group had recorded a turnover of €361.3 million in 2022, which included €280 million in revenue related to COVID-19 vaccine supply agreements.
(Writing by Diana Mandiá, editing by Kate Entringer)
Copyright © 2024 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
